Clinical Trial Update: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating itacitinib with alemtuzumab in recurrent T-cell prolymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Itacitinib (itacitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Status: COMPLETED